We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current JCRRF market cap is 532.2M. The company's latest EPS is JPY 44.4985 and P/E is 0.10.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 24.78B | 30.09B | 51.08B | 34.34B | 42.87B |
| Operating Income | 3.25B | 8.27B | 19.94B | 4.98B | 6.44B |
| Net Income | 2.68B | 6.89B | 14.51B | 3.77B | 5.51B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 47.78B | 73.78B | 97.13B | 94.94B | 102.23B |
| Total Liabilities | 15.2B | 35.23B | 46.05B | 42.52B | 45.75B |
| Total Equity | 32.58B | 38.56B | 51.09B | 52.41B | 56.48B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 4.93B | 10.34B | 9.29B | -5.5B | 9.31B |
| Investing | -4.16B | -3.29B | -3.25B | -15B | -2.69B |
| Financing | 2.05B | 8.3B | -2.18B | 1.95B | -2.03B |
| Market Cap | 532.2M |
| Price to Earnings Ratio | 0.10 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 0.03 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 123.76M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -54.59% |
| 52 Week High | 10.11 |
| 52 Week Low | 4.3004 |
| Spread (Intraday) | 0.84 (18.96%) |
| Company Name | JCR Pharmaceuticals Company Ltd (PK) |
| Address |
3-19 kasuga-cho ashiya, hyogo 659-0021 |
| Website | https://www.jcrpharm.co.jp |
| Industry | pharmaceutical biolog/vaccines (H23) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
